City of Hope and Institute for Follicular Lymphoma Innovation (IFLI) Announce $2 Million Research Program in Follicular Lymphoma
2024年7月31日 - 1:21AM
ビジネスワイヤ(英語)
Three-year research program will use patient data, DNA profiling
and other advanced techniques to study why spontaneous remission in
follicular lymphoma occurs
City of Hope®, one of the largest and most advanced cancer
research and treatment organizations in the United States, and
Institute for Follicular Lymphoma Innovation (IFLI) today announced
a $2 million, three-year collaboration to study spontaneous
remission in follicular lymphoma, the most common, slow-growing
non-Hodgkin's lymphoma.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240730507515/en/
Raju K. Pillai, M.D., City of Hope associate clinical professor,
Department of Pathology, and director, Pathology Research Services
Core Laboratories, and Steven T. Rosen, M.D., executive vice
president and director emeritus of City of Hope’s comprehensive
cancer center and its Beckman Research Institute, professor,
Department of Hematology & Hematopoietic Cell Transplantation,
and Ted Schwartz Family Distinguished Chair in Hematologic
Malignancies, will lead the research. The collaboration aims to
understand the tumor microenvironment in patients whose follicular
lymphoma goes into remission without any treatment while being
monitored over time.
City of Hope will analyze patient samples of follicular lymphoma
and spontaneous remission of follicular lymphoma with leading-edge
technologies, such as spatial proteomics and transcriptomics, as
well as machine learning techniques to help explain why spontaneous
remission of follicular lymphoma occurs in a rare number of
patients and not in others. The study aims to determine the most
relevant prognostic genetic, transcriptomic and microenvironmental
factors involved in spontaneous remission of follicular
lymphoma.
“Spontaneous remission in follicular lymphoma is not understood
and we are excited and humbled to collaborate and support City of
Hope’s prestigious team to leverage their expertise and suite of
technologies and assays to better understand this phenomenon,” said
Michel Azoulay, M.D., M.B.A., IFLI’s chief medical officer. “IFLI
is committed to funding innovative research projects, such as these
important studies at City of Hope, to better understand follicular
lymphoma and how we can improve treatments and outcomes for
follicular lymphoma patients.”
“The clinical spectrum of follicular lymphoma, which ranges from
spontaneous regression on one end to highly aggressive disease at
the other end, is influenced by the immune microenvironment to a
large extent,” Dr. Pillai said. “With IFLI’s support, we can study
follicular lymphoma, leveraging City of Hope’s omics and spatial
biology expertise to shed more light on why and how spontaneous
remission occurs, with the goal that our discoveries will translate
to advances in diagnostics and the next generation of therapies for
patients with follicular lymphoma.”
“I have shared the joy of my patients who have spontaneously
achieved remission, and I have shared the worry, anguish and
frustration of my patients whose follicular lymphoma has progressed
or transformed,” Dr. Rosen added. “I am thrilled to join with Dr.
Pillai, IFLI and other collaborators to help answer the question
‘Why certain patients and not all?’”
About the Institute for Follicular Lymphoma
Innovation
The Institute for Follicular Lymphoma Innovation (IFLI) is a
global non-profit, private foundation dedicated to accelerating the
development of innovative treatment options for patients with
follicular lymphoma. IFLI supports cutting-edge research and
technology to lead to the development and commercialization of
novel therapeutics and/or biomarkers for the treatment of
follicular lymphoma (FL), and to understand the biology of
follicular lymphoma. The foundation deploys its budget across
grants, project-based partnerships, and venture philanthropy
investments to achieve its innovation goals. IFLI aims to promote
data sharing among researchers and institutions working on
different aspects of follicular lymphoma research, fostering
collaboration, and enabling the exchange of knowledge and
expertise. Learn more at IFLI - The Institute for Follicular
Lymphoma Innovation (i-fli.org).
About City of Hope
City of Hope's mission is to make hope a reality for all touched
by cancer and diabetes. Founded in 1913, City of Hope has grown
into one of the largest cancer research and treatment organizations
in the U.S. and one of the leading research centers for diabetes
and other life-threatening illnesses. City of Hope research has
been the basis for numerous breakthrough cancer medicines, as well
as human synthetic insulin and monoclonal antibodies. With an
independent, National Cancer Institute-designated comprehensive
cancer center at its core, City of Hope’s uniquely integrated model
spans cancer care, research and development, academics and
training, and a broad philanthropy program that powers its work.
City of Hope’s growing national system includes its Los Angeles
campus, a network of clinical care locations across Southern
California, a new cancer center in Orange County, California, and
cancer treatment centers and outpatient facilities in the Atlanta,
Chicago and Phoenix areas. City of Hope’s affiliated group of
organizations includes Translational Genomics Research Institute
and AccessHopeTM. For more information about City of Hope, follow
us on Facebook, X, YouTube, Instagram and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730507515/en/
Letisia Marquez lemarquez@coh.org 626-476-7593
Beth Fordham-Meier beth@i-fli.org